evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 16 findings · 1 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 18.8%GRADE not reported 1 · 6.3%Very low 6 · 37.5%Low 6 · 37.5%Moderate 0 · 0%High 0 · 0%

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + GLP1‐A
2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + DPP4‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + DPP4‐I compared with metformin plus another antidiabetic drug (very low certainty).

3 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + thiazolidinedione

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + thiazolidinedione compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + nateglinide
4 findings from 1 review
Show 1 more finding

Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug

M + SGLT2‐I

It is very uncertain whether metformin‐sulphonylurea (second‐ or third‐generation) combination… changes M + SGLT2‐I compared with metformin plus another antidiabetic drug (very low certainty).

2 findings from 1 review